🔗 Share this article Individuals Discontinuing Weight-Loss Jabs Regain Pounds Four Times Faster Compared to Dieters Obesity treatment involves ongoing approaches. Fresh analysis reveals that people who discontinue popular weight-loss injections like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who end conventional diet and exercise programs. Research printed in a prominent medical journal demonstrates that while obese individuals often shed substantial amounts of their body weight while on the medication, the weight returns at an estimated rate of nearly a kilo each month once they quit. "Users buying these medications should be cognizant of the risk of fast rebound weight gain when the medication ends," cautioned expert Dr. Susan Jebb. This pace of recovery implies a return to original mass in about a year and a half. Weighing Treatments The study, which examined dozens of trials involving over 9,000 of participants, compared the effects of GLP-1 agonists with conventional dieting. Researchers emphasize that individuals who lose weight through diet and exercise typically have a more gradual creep back—around 0.1 kg a month—after stopping. Understanding the Quick Regain Experts suggest the mechanism of the jabs is key to understanding the accelerated rebound. GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates hunger. "Sustained high doses of the hormone levels far above than normal may cause the body to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher. "Withdrawal of this hormone supplement leads to appetite is uncontrolled, making binge eating a significant risk." A Chronic Issue? Health authorities suggest the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes. A number of clinicians argue that, given the high risk of relapse, the treatment is often long-term. This view is echoed by pharmaceutical companies, who note that the findings "underscore the chronic character of obesity," similar to managing conditions like high blood pressure. User Accounts Individuals who have stopped the medication explain a intense resurgence of appetite. "It felt as if a switch flipping and you're instantly ravenous," described a patient. This challenge is compounded if individuals have not established lasting lifestyle or habit modifications during therapy. Significant Use Recent estimates indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow. Adoption is more common among females than males. The middle-aged age group shows the greatest level of interest. A large proportion obtain the medications through private healthcare rather than public health services. Finally, researchers emphasize that while the jabs are potent tools for shedding pounds, they are not a standalone cure and long-term success relies on ongoing behavioural management.
Obesity treatment involves ongoing approaches. Fresh analysis reveals that people who discontinue popular weight-loss injections like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who end conventional diet and exercise programs. Research printed in a prominent medical journal demonstrates that while obese individuals often shed substantial amounts of their body weight while on the medication, the weight returns at an estimated rate of nearly a kilo each month once they quit. "Users buying these medications should be cognizant of the risk of fast rebound weight gain when the medication ends," cautioned expert Dr. Susan Jebb. This pace of recovery implies a return to original mass in about a year and a half. Weighing Treatments The study, which examined dozens of trials involving over 9,000 of participants, compared the effects of GLP-1 agonists with conventional dieting. Researchers emphasize that individuals who lose weight through diet and exercise typically have a more gradual creep back—around 0.1 kg a month—after stopping. Understanding the Quick Regain Experts suggest the mechanism of the jabs is key to understanding the accelerated rebound. GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates hunger. "Sustained high doses of the hormone levels far above than normal may cause the body to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher. "Withdrawal of this hormone supplement leads to appetite is uncontrolled, making binge eating a significant risk." A Chronic Issue? Health authorities suggest the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes. A number of clinicians argue that, given the high risk of relapse, the treatment is often long-term. This view is echoed by pharmaceutical companies, who note that the findings "underscore the chronic character of obesity," similar to managing conditions like high blood pressure. User Accounts Individuals who have stopped the medication explain a intense resurgence of appetite. "It felt as if a switch flipping and you're instantly ravenous," described a patient. This challenge is compounded if individuals have not established lasting lifestyle or habit modifications during therapy. Significant Use Recent estimates indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow. Adoption is more common among females than males. The middle-aged age group shows the greatest level of interest. A large proportion obtain the medications through private healthcare rather than public health services. Finally, researchers emphasize that while the jabs are potent tools for shedding pounds, they are not a standalone cure and long-term success relies on ongoing behavioural management.